Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Quick Stats
Studies 702
Trials 0
Score 4
1996 pubmed 10 citations

Growth hormone (GH)-releasing peptide and GH releasing hormone stimulate GH release from subpopulations of somatotrophs in rats.

Mitani. M M; Kaji. H H; Abe. H H; Chihara. K K

Key Findings

  • GHRP-6 (100 nM) significantly raises the percentage of pituitary cells releasing GH and the amount each cell releases.
  • When GHRP-6 is combined with GHRH, total GH output is higher than either alone, but the effect is additive, not synergistic.
  • There are distinct subpopulations of somatotroph cells: some respond only to GHRH, some only to GHRP-6, and a few respond to both.

Practical Outcomes

  • For biohackers, this study supports using GHRP-6 as an effective GH secretagogue on its own and suggests that pairing it with a GHRH analog (like CJC‑1295) can further increase GH levels, though you shouldn’t expect exponential gains. The data also imply that individual response may vary because of different pituitary cell sensitivities, so personal experimentation with dosing and combination is warranted.

Summary

In rats, the peptide GHRP-6 directly makes the pituitary gland release more growth hormone, and it works together with the natural hormone GHRH to give an even bigger boost, although the two just add up rather than multiply each other's effects. Different groups of hormone‑producing cells respond to GHRP-6, GHRH, or both, showing that the peptide has its own pathway for triggering growth hormone.

Abstract

The synthetic hexapeptide GH-releasing peptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2; GHRP-6) and GH releasing hormone (GHRH) are both potent stimulators of GH release in rats. Using reverse hemolytic plaque assay (RHPA), we have compared the effects of human GHRH and GHRP-6 on GH release from the dispersed individual cells of rat anterior pituitary. In a single RHPA, we quantified the percentage of plaque forming cells (% PFC) and their mean plaque area (MPA) after 30 min-incubation, and calculated a total secretion index (TSI) by multiplying % PFC and MPA. 10 nM GHRH and 100 nM GHRP-6 each caused a significant increase in % PFC (%) (GHRH 39.15, GHRP-6 29.4, vs vehicle 24.3, P < 0.01), MPA (x 10(-2) microns2) (GHRH 124.04, GHRP-6 94.80, vs vehicle 44.57, P < 0.01) and TSI (x 10(-2)) (GHRP-6 32.87, vs vehicle 10.84, P < 0.01). Simultaneous addition of both secretagogues caused a further increase in GH release (%PFC 46.4, MPA 142.55, TSI 69.82, P < 0.01 vs vehicle), although the effect was additive but not synergistic. Somatostatin analog, SMS201-995 (SMS) partially suppressed all parameters in GH secretion after stimulation by GHRH and/or GHRP-6. A double RHPA was then performed to test whether all somatotrophs respond equally to GHRH and GHRP-6 or some cells formed plaques only be either GHRH or GHRP-6. There were somatotrophs responsive to only GHRH (23.3% vs control 6.2%, P < 0.01), those responsive to only GHRP-6 (11.9% vs control 6.1%, P < 0.01), and those responsive to both GHRH and GHRP-6 (7.8% vs control 0.2%, P < 0.01). These results confirmed the previous findings that GHRP-6 and GHRH directly but independently stimulate GH release from the pituitary cells, and further suggest that presence of at least three functionally distinct somatotroph subpopulations concerning the responsiveness to GHRP-6 and GHRH in rats.

Study Information

Provider

pubmed

Year

1996

Date

1996-11-01T00:00:00.000Z

DOI

10.1046/j.1365-2826.1996.05283.x

Citations

10

References

31